Merck Lumira Biosciences Fund seeds newly formed OsteoQC

OsteoQC, a newly formed company that develops drug therapies for the treatment of bone-related diseases, has closed a seed-stage financing. The round, the amount of which was not disclosed, was led by the Merck Lumira Biosciences Fund, a fund managed by Lumira Capital, a Canadian life sciences venture capital firm. The Montréal-based OsteoQC, which is led by Dr. Debra Ellies, said the proceeds will enable the advance of its lead small molecule product candidate for bone formation. Lumira managing director Dr. Brian Underdown is the company's chairman, while managing director Dr. Daniel Hetu is its vice-chairman.

CanadaNorth AmericaBriefs